The NCCN Oncology Research Program has awarded grants for its first-ever multi-industry collaborative project, soliciting investigator-initiated proposals to research the effectiveness of Boehringer Ingelheim’s afatinib in combination with other drugs to treat lung and head and neck cancers.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
